Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses

Bibliography

• Dimitrov DS. Virus entry: molecular mechanisms and biomedical applications. Nat Rev Microbiol 2004;2:109-22
   PubMed Web of Science ®Google Scholar
• Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2004;2:695-703
   PubMed Web of Science ®Google Scholar
• Casadevall A. Passive antibody therapies: progress and continuing challenges. Clin Immunol 1999;93:5-15
   PubMed Web of Science ®Google Scholar
• Casadevall A, Scharff MD. Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis 1995;21:150-61
   PubMed Web of Science ®Google Scholar
• Casadevall A, Scharff MD. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother 1994;38:1695-702
   PubMed Web of Science ®Google Scholar
• Zeitlin L, Cone RA, Moench TR, Whaley KJ. Preventing infectious disease with passive immunization. Microb Infect 2000;2:701-8
   PubMed Web of Science ®Google Scholar
• Sawyer LA. Antibodies for the prevention and treatment of viral diseases. Antiviral Res 2000;47:57-77
   PubMed Web of Science ®Google Scholar
• Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era? Trends Pharmacol Sci 2004;25:306-10
   PubMed Web of Science ®Google Scholar
• DesJardin JA, Snydman DR. Antiviral immunotherapy – a review of current status. Biodrugs 1998;9:487-507
   PubMed Web of Science ®Google Scholar
• Moudgil A, Shidban H, Nast CC, et al. Parvovirus B19 infection-related complications in renal transplant recipients: treatment with intravenous immunoglobulin. Transplantation 1997;64:1847-50
   PubMed Web of Science ®Google Scholar
• Kurtzman G, Frickhofen N, Kimball J, et al. Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 1989;321:519-23
   PubMed Web of Science ®Google Scholar
• Kerr JR, Cunniffe VS, Kelleher P, et al. Successful intravenous immunoglobulin therapy in 3 cases of parvovirus B19-associated chronic fatigue syndrome. Clin Infect Dis 2003;36:e100-6
   PubMed Web of Science ®Google Scholar
• Koduri PR, Kumapley R, Valladares J, Teter C. Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: use of intravenous immunoglobulin–a report of eight patients. Am J Hematol 1999;61:16-20
   PubMed Web of Science ®Google Scholar
• Clayton AJ. Lassa immune serum. Bull World Health Organ 1977;55:435-9
   PubMed Web of Science ®Google Scholar
• Krasnianskii VP, Gradoboev VN, Borisevich IV, et al. Development and study of properties of immunoglobulins against Lassa fever. Vopr Virusol 1997;42:168-71
   PubMed Web of Science ®Google Scholar
• Shimoni Z, Niven MJ, Pitlick S, Bulvik S. Treatment of West Nile virus encephalitis with intravenous immunoglobulin. Emerg Infect Dis 2001;7:759
   PubMed Web of Science ®Google Scholar
• Hamdan A, Green P, Mendelson E, et al. Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile virus encephalitis. Transpl Infect Dis 2002;4:160-2
   PubMedGoogle Scholar
• Pasic S, Jankovic B, Abinun M, Kanjuh B. Intravenous immunoglobulin prophylaxis in an echovirus 6 and echovirus 4 nursery outbreak. Pediatr Infect Dis J 1997;16:718-20
   PubMed Web of Science ®Google Scholar
• Rotbart HA, O'Connell JF, McKinlay MA. Treatment of human enterovirus infections. Antiviral Res 1998;38:1-14
   PubMed Web of Science ®Google Scholar
• Masci S, De Simone C, Famularo G, et al. Intravenous immunoglobulins suppress the recurrences of genital herpes simplex virus: a clinical and immunological study. Immunopharmacol Immunotoxicol 1995;17:33-47
   PubMed Web of Science ®Google Scholar
• Vassilenko SM, Vassilev TL, Bozadjiev LG, et al. Specific intravenous immunoglobulin for Crimean-Congo haemorrhagic fever. Lancet 1990;335:791-2
   PubMed Web of Science ®Google Scholar
• Enria DA, Briggiler AM, Fernandez NJ, et al. Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma. Lancet 1984;2:255-6
   PubMed Web of Science ®Google Scholar
• Ali MB. Treating severe acute respiratory syndrome with hyperimmune globulins. Hong Kong Med J 2003;9:391-2
   PubMedGoogle Scholar
• Burnouf T, Radosevich M. Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J 2003;9:309
   PubMedGoogle Scholar
• Vittecoq D, Chevret S, Morand-Joubert L, et al. Passive immunotherapy in AIDS: a double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs. transfusions of seronegative plasma. Proc Natl Acad Sci USA 1995;92:1195-9
   PubMed Web of Science ®Google Scholar
• Jablonowski H, Sander O, Willers R, et al. The use of intravenous immunoglobulins in symptomatic HIV infection. Results of a randomized study. Clin Investig 1994;72:220-4
   PubMedGoogle Scholar
• Olopoenia L, Young M, White D, et al. Intravenous immunoglobulin in symptomatic and asymptomatic children with perinatal HIV infection. J Natl Med Assoc 1997;89:543-7
   PubMed Web of Science ®Google Scholar
• Guay LA, Musoke P, Hom DL, et al. Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in Uganda. AIDS 2002;16:1391-400
   PubMed Web of Science ®Google Scholar
• Dezube BJ, Proper J, Zhang J, et al. A passive immunotherapy, PEHRG214, in patients infected with human immunodeficiency virus: a Phase I study. J Infect Dis 2003;187:500-3
   PubMed Web of Science ®Google Scholar
• Zolla-Pazner S, Gorny MK. Passive immunization for the prevention and treatment of HIV infection. AIDS 1992;6:1235-47
   PubMed Web of Science ®Google Scholar
• Wu H, Pfarr DS, Tang Y, et al. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J Mol Biol 2005;350:126-44
   PubMed Web of Science ®Google Scholar
• Saez-Llorens X, Moreno MT, Ramilo O, et al. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr Infect Dis J 2004;23:707-12
   PubMed Web of Science ®Google Scholar
• Zhao X, Sullender WM. In vivo selection of respiratory syncytial viruses resistant to palivizumab. J Virol 2005;79:3962-8
   PubMed Web of Science ®Google Scholar
• Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003;348:1953-66
   PubMed Web of Science ®Google Scholar
• Peiris JS, Lai ST, Poon LL, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003;361:1319-25
   PubMed Web of Science ®Google Scholar
• Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;348:1967-76
   PubMed Web of Science ®Google Scholar
• Holmes KV. SARS-associated coronavirus. N Engl J Med 2003;348:1948-51
   PubMed Web of Science ®Google Scholar
• Hsueh PR, Huang LM, Chen PJ, et al. Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. Clin Microbiol Infect 2004;10:1062-6
   PubMed Web of Science ®Google Scholar
• Nie Y, Wang G, Shi X, et al. Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection. J Infect Dis 2004;190:1119-26
   PubMed Web of Science ®Google Scholar
• Shi Y, Wan Z, Li L, et al. Antibody responses against SARS-coronavirus and its nucleocaspid in SARS patients. J Clin Virol 2004;31:66-8
   PubMed Web of Science ®Google Scholar
• Han DP, Kim HG, Kim YB, et al. Development of a safe neutralization assay for SARS-CoV and characterization of S-glycoprotein. Virology 2004;326:140-9
   PubMed Web of Science ®Google Scholar
• Guo JP, Petric M, Campbell W, McGeer PL. SARS corona virus peptides recognized by antibodies in the sera of convalescent cases. Virology 2004;324:251-6
   PubMed Web of Science ®Google Scholar
• Hofmann H, Hattermann K, Marzi A, et al. S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients. J Virol 2004;78:6134-42
   PubMed Web of Science ®Google Scholar
• Subbarao K, McAuliffe J, Vogel L, et al. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol 2004;78:3572-7
   PubMed Web of Science ®Google Scholar
• Roberts A, Vogel L, Guarner J, et al. Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters. J Virol 2005;79:503-11
   PubMed Web of Science ®Google Scholar
• Mcauliffe J, Vogel L, Roberts A, et al. Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys. Virology 2004;330:8-15
   PubMed Web of Science ®Google Scholar
• Zhou T, Wang H, Luo D, et al. An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies. J Virol 2004;78:7217-26
   PubMed Web of Science ®Google Scholar
• Zhang H, Wang G, Li J, et al. Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies. J Virol 2004;78:6938-45
   PubMed Web of Science ®Google Scholar
• Yao YX, Ren J, Heinen P, et al. Cleavage and serum reactivity of the severe acute respiratory syndrome coronavirus spike protein. J Infect Dis 2004;190:91-8
   PubMed Web of Science ®Google Scholar
• Zeng F, Chow KY, Hon CC, et al. Characterization of humoral responses in mice immunized with plasmid DNAs encoding SARS-CoV spike gene fragments. Biochem Biophys Res Commun 2004;315:1134-9
   PubMed Web of Science ®Google Scholar
• Yang ZY, Kong WP, Huang Y, et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 2004;428:561-4
   PubMed Web of Science ®Google Scholar
• Bisht H, Roberts A, Vogel L, et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci USA 2004;101:6641-6
   PubMed Web of Science ®Google Scholar
• Qu D, Zheng B, Yao X, et al. Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice. Vaccine 2005;23:924-31
   PubMed Web of Science ®Google Scholar
• Xiong S, Wang YF, Zhang MY, et al. Immunogenicity of SARS inactivated vaccine in BALB/c mice. Immunol Lett 2004;95:139-43
   PubMed Web of Science ®Google Scholar
• He Y, Zhou Y, Wu H, et al. Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines. J Immunol 2004;173:4050-7
   PubMed Web of Science ®Google Scholar
• Takasuka N, Fujii H, Takahashi Y, et al. A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. Int Immunol 2004;16:1423-30
   PubMed Web of Science ®Google Scholar
• Tang L, Zhu Q, Qin E, et al. Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice. DNA Cell Biol 2004;23:391-4
   PubMed Web of Science ®Google Scholar
• Buchholz UJ, Bukreyev A, Yang L, et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci USA 2004;101:9804-9
   PubMed Web of Science ®Google Scholar
• He Y, Zhou Y, Siddiqui P, Jiang S. Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry. Biochem Biophys Res Commun 2004;325:445-52
   PubMed Web of Science ®Google Scholar
• Pang H, Liu Y, Han X, et al. Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: implications for the design of an effective protein-based vaccine. J Gen Virol 2004;85:3109-13
   PubMed Web of Science ®Google Scholar
• Weingartl H, Czub M, Czub S, et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol 2004;78:12672-6
   PubMed Web of Science ®Google Scholar
• Weingartl HM, Copps J, Drebot MA, et al. Susceptibility of pigs and chickens to SARS coronavirus. Emerg Infect Dis 2004;10:179-84
   PubMed Web of Science ®Google Scholar
• Gao W, Tamin A, Soloff A, et al. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet 2003;362:1895-6
   PubMed Web of Science ®Google Scholar
• Bukreyev A, Lamirande EW, Buchholz UJ, et al. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 2004;363:2122-7-
   PubMed Web of Science ®Google Scholar
• Xiao X, Dimitrov DS. The SARS-CoV S glycoprotein. Cell Mol Life Sci 2004;61:2428-30
   PubMed Web of Science ®Google Scholar
• Berry JD, Jones S, Drebot MA, et al. Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus. J Virol Methods 2004;120:87-96
   PubMed Web of Science ®Google Scholar
• Gubbins MJ, Plummer FA, Yuan XY, et al. Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus. Mol Immunol 2005;42:125-36
   PubMed Web of Science ®Google Scholar
• Murray K, Selleck P, Hooper P, et al. A morbillivirus that caused fatal disease in horses and humans. Science 1995;268:94-7
   PubMed Web of Science ®Google Scholar
• Lee KE, Umapathi T, Tan CB, et al. The neurological manifestations of Nipah virus encephalitis, a novel paramyxovirus. Ann Neurol 1999;46:428-32
   PubMed Web of Science ®Google Scholar
• Lim CC, Sitoh YY, Hui F, et al. Nipah viral encephalitis or Japanese encephalitis? MR findings in a new zoonotic disease. AJNR Am J Neuroradiol 2000;21:455-61
   PubMed Web of Science ®Google Scholar
• Chua KB, Goh KJ, Wong KT, et al. Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia. Lancet 1999;354:1257-9
   PubMed Web of Science ®Google Scholar
• Chew MH, Arguin PM, Shay DK, et al. Risk factors for Nipah virus infection among abattoir workers in Singapore. J Infect Dis 2000;181:1760-3
   PubMed Web of Science ®Google Scholar
• Chua KB, Lam SK, Tan CT, et al. High mortality in Nipah encephalitis is associated with presence of virus in cerebrospinal fluid. Ann Neurol 2000;48:802-5
   PubMed Web of Science ®Google Scholar
• Goh KJ, Tan CT, Chew NK, et al. Clinical features of Nipah virus encephalitis among pig farmers in Malaysia. N Engl J Med 2000;342:1229-35
   PubMed Web of Science ®Google Scholar
• Update: outbreak of Nipah virus–Malaysia and Singapore, 1999. MMWR Morb Mortal Wkly Rep 1999;48:335-7
   PubMedGoogle Scholar
• Chua KB, Bellini WJ, Rota PA, et al. Nipah virus: a recently emergent deadly paramyxovirus. Science 2000;288:1432-5
   PubMed Web of Science ®Google Scholar
• Eaton BT. Introduction to Current focus on Hendra and Nipah viruses. Microb Infect 2001;3:277-8
   PubMed Web of Science ®Google Scholar
• Eaton BT, Broder CC, Middleton D, Wang LF. Hendra and Nipah viruses: different and dangerous. Nat Rev Microbiol 2006;4:23-35
   PubMed Web of Science ®Google Scholar
• Bossart KN, Broder CC. Developments towards effective treatments for Nipah and Hendra virus infection. Expert Rev Anti Infect Ther 2006;4:43-55
   PubMedGoogle Scholar
• Bossart KN, McEachern JA, Hickey AC, et al. Neutralization assays for differential henipavirus serology using Bio-Plex protein array systems. J Virol Methods 2007;142:29-40
   PubMed Web of Science ®Google Scholar
• Guillaume V, Contamin H, Loth P, et al. Nipah virus: vaccination and passive protection studies in a hamster model. J Virol 2004;78:834-40
   PubMed Web of Science ®Google Scholar
• Bossart KN, Crameri G, Dimitrov AS, et al. Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus. J Virol 2005;79:6690-702
   PubMed Web of Science ®Google Scholar
• Guillaume V, Contamin H, Loth P, et al. Antibody prophylaxis and therapy against Nipah virus infection in hamsters. J Virol 2006;80:1972-8
   PubMed Web of Science ®Google Scholar
• Zhang MY, Choudhry V, Xiao X, Dimitrov DS. Human monoclonal antibodies to the S glycoprotein and related proteins as potential therapeutics for SARS. Curr Opin Mol Ther 2005;7:151-6
   PubMed Web of Science ®Google Scholar
• Traggiai E, Becker S, Subbarao K, et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 2004;10:871-5
   PubMed Web of Science ®Google Scholar
• Yang ZY, Werner HC, Kong WP, et al. Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc Natl Acad Sci USA 2005;102:797-801
   PubMed Web of Science ®Google Scholar
• Sui J, Li W, Murakami A, et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci USA 2004;101:2536-41
   PubMed Web of Science ®Google Scholar
• Hwang WC, Lin YQ, Santelli E, et al. Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R. J Biol Chem 2006;281:34610-6
   PubMed Web of Science ®Google Scholar
• Sui J, Li W, Roberts A, et al. Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. J Virol 2005;79:5900-6
   PubMed Web of Science ®Google Scholar
• ter Meulen J, Bakker AB, van den Brink EN, et al. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 2004;363:2139-41
   PubMed Web of Science ®Google Scholar
• van den Brink EN, ter Meulen J, Cox F, et al. Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus. J Virol 2005;79:1635-44
   PubMed Web of Science ®Google Scholar
• Ter MJ, van den Brink EN, Poon LL, et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med 2006;3:e237. Published online July 4 2006, doi:10.1371/journal.pmed.0030237
   PubMed Web of Science ®Google Scholar
• Greenough TC, Babcock GJ, Roberts A, et al. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J Infect Dis 2005;191:507-14
   PubMed Web of Science ®Google Scholar
• Prabakaran P, Gan J, Feng Y, et al. Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody. J Biol Chem 2006;281:15829-36
   PubMed Web of Science ®Google Scholar
• Xiao X, Chakraborti S, Dimitrov AS, et al. The SARS-CoV S glycoprotein: expression and functional characterization. Biochem Biophys Res Commun 2003;312:1159-64
   PubMed Web of Science ®Google Scholar
• Chakraborti S, Prabakaran P, Xiao X, Dimitrov DS. The SARS coronavirus S glycoprotein receptor binding domain: fine mapping and functional characterization. Virol J 2005;2:73. Published online August 25 2005, doi:10.1186/1743-422X-2-73
   PubMed Web of Science ®Google Scholar
• Wong SK, Li W, Moore MJ, et al. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem 2004;279:3197-201
   PubMed Web of Science ®Google Scholar
• He Y, Zhou Y, Liu S, et al. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun 2004;324:773-81
   PubMed Web of Science ®Google Scholar
• Jiang S, He Y, Liu S. SARS vaccine development. Emerg Infect Dis 2005;11:1016-20
   PubMed Web of Science ®Google Scholar
• He Y, Lu H, Siddiqui P, et al. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol 2005;174:4908-15
   PubMed Web of Science ®Google Scholar
• He Y, Zhu Q, Liu S, et al. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines. Virology 2005;334:74-82
   PubMed Web of Science ®Google Scholar
• Chen Z, Zhang L, Qin C, et al. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J Virol 2005;79:2678-88
   PubMed Web of Science ®Google Scholar
• Yi CE, Ba L, Zhang L, et al. Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain. J Virol 2005;79:11638-46
   PubMed Web of Science ®Google Scholar
• Zhu ZY, Chakraborti S, He Y, et al. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci USA 2007;104:12123-8
   PubMed Web of Science ®Google Scholar
• Duan J, Yan X, Guo X, et al. A human SARS-CoV neutralizing antibody against epitope on S2 protein. Biochem Biophys Res Commun 2005;333:186-93
   PubMed Web of Science ®Google Scholar
• Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003;426:450-4
   PubMed Web of Science ®Google Scholar
• Li W, Shi Z, Yu M, et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 2005;310:676-9
   PubMed Web of Science ®Google Scholar
• Lau SK, Woo PC, Li KS, et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci USA 2005;102:14040-5
   PubMed Web of Science ®Google Scholar
• Li F, Li W, Farzan M, Harrison SC. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 2005;309:1864-8
   PubMed Web of Science ®Google Scholar
• Zhu Z, Dimitrov AS, Bossart KN, et al. Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies. J Virol 2006;80:891-9
   PubMed Web of Science ®Google Scholar
• Bonaparte MI, Dimitrov AS, Bossart KN, et al. Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus. Proc Natl Acad Sci USA 2005;102:10652-7
   PubMed Web of Science ®Google Scholar
• Negrete OA, Levroney EL, Aguilar HC, et al. EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus. Nature 2005;436:401-5
   PubMed Web of Science ®Google Scholar
• Xu K, Rajashankar KR, Chan YP, et al. Host cell recognition by the henipaviruses: Crystal structures of the Nipah G attachment glycoprotein and its complex with ephrin-B3. Proc Natl Acad Sci USA 2008;105:9953-8
   PubMed Web of Science ®Google Scholar
• Bowden TA, Aricescu AR, Gilbert RJC, et al. Structural basis of Nipah and Hendra virus attachment to their cell-surface receptor ephrin-B2. Nat Struct Mol Biol 2008;15:567-72
   PubMed Web of Science ®Google Scholar
• Kwong PD, Wyatt R, Robinson J, et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998;393:648-59
   PubMed Web of Science ®Google Scholar
• Zhou TQ, Xu L, Dey B, et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007;445:732-7
   PubMed Web of Science ®Google Scholar
• Zhu Z, Bossart KN, Bishop KA, et al. Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody. J Infect Dis 2008;197:846-53
   PubMed Web of Science ®Google Scholar